FibroGen Inc. (NASDAQ:FGEN) Director Thomas F. Kearns, Jr. sold 18,000 shares of FibroGen stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $22.40, for a total transaction of $403,200.00. Following the completion of the sale, the director now directly owns 165,564 shares in the company, valued at approximately $3,708,633.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of FibroGen Inc. (NASDAQ:FGEN) opened at 23.05 on Tuesday. FibroGen Inc. has a one year low of $14.38 and a one year high of $31.90. The company’s market cap is $1.46 billion. The firm’s 50-day moving average is $18.89 and its 200-day moving average is $18.43.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.21. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. The company earned $30.10 million during the quarter, compared to the consensus estimate of $24.30 million. On average, equities analysts anticipate that FibroGen Inc. will post ($0.99) EPS for the current year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

A number of hedge funds have recently modified their holdings of FGEN. Candriam Luxembourg S.C.A. increased its stake in shares of FibroGen by 77.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 481,000 shares of the biopharmaceutical company’s stock valued at $9,957,000 after buying an additional 210,000 shares during the period. Doheny Asset Management CA increased its stake in shares of FibroGen by 44.1% in the third quarter. Doheny Asset Management CA now owns 28,000 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 8,575 shares during the period. Panagora Asset Management Inc. increased its stake in shares of FibroGen by 274.5% in the third quarter. Panagora Asset Management Inc. now owns 51,802 shares of the biopharmaceutical company’s stock valued at $1,072,000 after buying an additional 37,968 shares during the period. Hillhouse Capital Management Ltd. purchased a new stake in shares of FibroGen during the third quarter valued at about $10,612,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of FibroGen during the third quarter valued at about $753,000. 50.07% of the stock is owned by institutional investors.

FGEN has been the topic of a number of analyst reports. Credit Suisse Group AG reissued a “buy” rating and set a $37.00 target price on shares of FibroGen in a report on Tuesday, August 9th. Leerink Swann reissued a “buy” rating and set a $52.00 target price on shares of FibroGen in a report on Wednesday, November 9th. Finally, Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Friday, November 11th.

FibroGen Company Profile

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Stock Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related stocks with our FREE daily email newsletter.